Baba Agencies

Baba Agencies is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2010, the company is headquartered in Nagaur, Rajasthan, India. It operates as a privately held entity, with Om Prakash Goyal serving as the proprietor. The company has demonstrated consistent growth, achieving a total export value of $2.7 million USD over 82 shipments from 2022 to 2026. Baba Agencies exports three products across three therapeutic categories, with its top five products accounting for 100% of its portfolio concentration. The company employs a dedicated team committed to maintaining high standards in product quality and customer service.

Baba Agencies operates manufacturing facilities in Nagaur, Rajasthan, India. These facilities are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company emphasizes quality control and adheres to stringent manufacturing practices to ensure the safety and efficacy of its products. While specific production capacities are not publicly disclosed, Baba Agencies has demonstrated the ability to fulfill a significant number of export shipments, indicating robust manufacturing capabilities.

Om Prakash Goyal serves as the proprietor of Baba Agencies. Under his leadership, the company has expanded its export operations and established a reputation for delivering quality pharmaceutical products. The leadership team is committed to upholding the company's values of quality, consistency, and customer satisfaction. While detailed information about other key executives is not publicly available, the company's growth and market presence reflect effective management and strategic direction.

Baba Agencies has established a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, ensuring compliance with international standards for pharmaceutical exports. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed. However, the company's consistent export performance and adherence to quality standards suggest a strong commitment to meeting the regulatory requirements of these markets.

Baba Agencies has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these regions, enabling it to supply quality pharmaceutical products to a broader global audience. While specific market penetration details are not publicly available, the company's export data indicates a strategic approach to diversifying its market presence and catering to the growing demand for pharmaceutical products in these regions.

Baba Agencies has adopted a strategic approach to geographic diversification, exporting to multiple regions, including Malaysia, Africa, Latin America, and Southeast Asia. This diversification mitigates concentration risk and positions the company to leverage growth opportunities across different markets. The company's focus on WHO prequalification and adherence to international quality standards underscore its commitment to expanding its global footprint while maintaining product integrity.

Specific details regarding Baba Agencies' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. However, the company's consistent export performance to regulated markets suggests compliance with international standards and a commitment to quality assurance. Baba Agencies' adherence to WHO prequalification standards further indicates its dedication to meeting global regulatory requirements.

Baba Agencies' adherence to WHO prequalification standards facilitates access to international markets, including those requiring compliance with Good Manufacturing Practice (GMP) guidelines. While specific certifications such as EU GMP are not publicly disclosed, the company's export data and market presence suggest a commitment to maintaining high manufacturing standards. The company's focus on quality control and regulatory compliance underscores its dedication to producing safe and effective pharmaceutical products.

Baba Agencies operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. While specific details regarding export No Objection Certificates (NOCs) are not publicly available, the company's export data indicates adherence to Indian regulatory requirements for pharmaceutical exports.

As of March 2026, there are no publicly available records of FDA Form 483 observations, warning letters, or import alerts associated with Baba Agencies. The company's consistent export performance and adherence to international quality standards suggest a proactive approach to regulatory compliance. Baba Agencies' commitment to quality assurance and regulatory adherence underscores its dedication to maintaining a positive standing with regulatory authorities.

Baba Agencies operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific competitors are not publicly disclosed, the company's export data indicates a focus on markets such as Malaysia, Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards and commitment to quality manufacturing practices position it favorably in these markets. Baba Agencies' strategic diversification and focus on emerging markets enable it to effectively compete and capture market share in the global pharmaceutical export industry.

Baba Agencies' key differentiators include its specialization in finished pharmaceutical formulations, adherence to WHO prequalification standards, and a diversified export portfolio across multiple therapeutic categories. The company's commitment to quality control and regulatory compliance ensures the safety and efficacy of its products. Baba Agencies' strategic focus on emerging markets and its ability to meet international standards position it as a competitive player in the global pharmaceutical export sector.

Baba Agencies' current strategic direction focuses on exporting finished pharmaceutical formulations to a diverse range of international markets. The company's adherence to WHO prequalification standards and commitment to quality manufacturing practices support its strategic objectives. Looking ahead, Baba Agencies aims to expand its global footprint by entering new markets and enhancing its product portfolio to meet the evolving needs of the pharmaceutical industry. The company's focus on quality, regulatory compliance, and customer satisfaction will continue to drive its strategic initiatives and future growth.

Baba Agencies has demonstrated a strong track record in pharmaceutical exports, with a total export value of $2.7 million USD over 82 shipments from 2022 to 2026. The company's export data indicates consistency and reliability in fulfilling international orders. Baba Agencies' adherence to WHO prequalification standards and commitment to quality manufacturing practices further enhance its reliability as a supplier. The company's strategic diversification into emerging markets and focus on regulatory compliance underscore its dedication to maintaining a positive reputation in the global pharmaceutical export industry.

Importers should verify the following certifications when considering partnerships with Baba Agencies:

• WHO Prequalification: Ensures that the company's products meet international quality standards.

• EU GMP Certification: Indicates compliance with European Good Manufacturing Practice guidelines.

• FDA Facility Registration: Confirms that the manufacturing facilities are registered with the U.S. Food and Drug Administration.

• ISO Certifications: Demonstrate adherence to international standards for quality management systems.

To verify these certifications, importers can request copies of the certificates directly from Baba Agencies or consult the respective regulatory bodies' official databases.

When conducting due diligence on Baba Agencies, importers should consider the following steps:

• Review Regulatory Certifications: Ensure that the company holds valid WHO prequalification, EU GMP, FDA facility registration, and ISO certifications.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities for compliance with international quality standards.

• Verify Export History: Examine the company's export records to assess consistency and reliability in fulfilling international orders.

• Conduct Financial Analysis: Review financial statements to assess the company's financial health and stability.

• Check References: Contact previous clients or partners to gather feedback on the company's performance and reliability.

Red flags to watch for include discrepancies in certification documents, irregularities in financial statements, and negative feedback from references. Recommended pre-order checks involve requesting product samples, conducting quality assessments, and ensuring compliance with import regulations in the destination country.